AndreaBozzo/ceres-open-data-index huggingface dataset:
Behavioral Risk Factor Surveillance Survey: 2011

The Behavioral Risk Factor Surveillance System (BRFSS) is an annual statewide telephone surveillance system designed by the Centers for Disease Control and Prevention (CDC). BRFSS monitors modifiable risk behaviors and other factors contributing to the leading causes of morbidity and mortality in the population. New York State's BRFSS sample represents the non-institutionalized adult household population, aged 18 years and older.

Although the overall number of respondents in the BRFSS is more than sufficiently large for statistical inference purposes, subgroup analyses can lead to estimates that are unreliable. Interpreting and reporting weighted numbers that are based on a small, unweighted number of respondents can mislead the reader into believing that a given finding is much more precise than it actually is. The BRFSS follows a rule of not reporting or interpreting percentages based upon a denominator of fewer than 50 respondents (unweighted sample). Both a csv and sas data files are available.

For more information, check out http://www.health.ny.gov/statistics/brfss/.
Symptomatic hemorrhage after alteplase therapy not due to silent ischemia

Background
          Stroke thrombolysis-related intracerebral hemorrhage may occur remotely from the anatomical site of ischemia. One postulated mechanism for this is simultaneous multiple embolization with hemorrhage into a "silent" area of ischemia.
        
        
          Results
          A patient suffered a disabling stroke affecting the right cerebral hemisphere. He was treated with intravenous alteplase and underwent extensive early imaging with multimodal MRI. Several hours after treatment he developed a brainstem hemorrhage despite having no evidence of ischemia on DWI MRI in the brainstem.
        
        
          Conclusion
          Not all occurrences of remote ICH after stroke thrombolysis are secondary to multiple emboli with silent ischemia.
Compound 525701: p-Methoxybenzylidene-benzyl-amine

Chemical compound data from PubChem database. IUPAC Name: N-benzyl-1-(4-methoxyphenyl)methanimine. Molecular Formula: C15H15NO. Molecular Weight: 225.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: Nevada, 2014

This is a behavioral health report for the state of Nevada. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
Compound 527692: Butanoic acid, 3-chloro, 3-butenyl ester

Chemical compound data from PubChem database. IUPAC Name: but-3-enyl 3-chlorobutanoate. Molecular Formula: C8H13ClO2. Molecular Weight: 176.64. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
COVID-19 Vaccine Distribution Allocations by Jurisdiction - Janssen

New weekly allocations of doses are posted every Tuesday.  Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses.  Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders. 

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020. 

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Pfizer Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Initial-Allocations-Pfizer/saz5-9hgg

Moderna Vaccine Data- https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws
2004 National Nursing Home Survey - Restricted Current Resident Dataset

The 2004 National Nursing Home Survey (NNHS), conducted between August and December of 2004, was reintroduced into the field after a five-year break, during which time the survey was redesigned and expanded to collect many new data items. All nursing homes that participated in the NNHS had at least three beds and were either certified (by Medicare or Medicaid) or had a state license to operate as a nursing home. The redesigned survey was administered using a computer-assisted personal interviewing (CAPI) system. The National Nursing Home Survey provides information on nursing homes from two perspectives-that of the provider of services and that of the recipient of care. Data about the facilities include characteristics such as size, ownership, Medicare/Medicaid certification, services provided and specialty programs offered, and charges. For recipients, data were obtained on demographic characteristics, health status and medications taken, services received, and sources of payment.

Data for the survey were obtained through personal interviews with facility administrators and designated staff who used administrative records to answer questions about the facilities, staff, services and programs, and medical records to answer questions about the residents.

The total number of nursing home facilities that participated in NNHS is 1,174.
PLACES: Local Data for Better Health, ZCTA Data 2024 release

This dataset contains model-based ZIP Code Tabulation Area (ZCTA) level estimates. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. The dataset includes estimates for 40 measures: 12 for health outcomes, 7 for preventive services use, 4 for chronic disease-related health risk behaviors, 7 for disabilities, 3 for health status, and 7 for health-related scocial needs. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2020 population data, and American Community Survey 2018–2022 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. More information about the methodology can be found at   www.cdc.gov/places.
Compound 525836: N,N-Dimethyl-N'-benzyl-propionamidine

Chemical compound data from PubChem database. IUPAC Name: N'-benzyl-N,N-dimethylpropanimidamide. Molecular Formula: C12H18N2. Molecular Weight: 190.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Synthetic Healthcare Database for Research (SyH-DR)

The Agency for Healthcare Research and Quality (AHRQ) created SyH-DR from eligibility and claims files for Medicare, Medicaid, and commercial insurance plans in calendar year 2016. SyH-DR contains data from a nationally representative sample of insured individuals for the 2016 calendar year. SyH-DR uses synthetic data elements at the claim level to resemble the marginal distribution of the original data elements. SyH-DR person-level data elements are not synthetic, but identifying information is aggregated or masked.
Compound 526519: [6-[10,13-dimethyl-3,7-bis(trimethylsilyloxy)-6,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptoxy]-trimethylsilane

Chemical compound data from PubChem database. IUPAC Name: [6-[10,13-dimethyl-3,7-bis(trimethylsilyloxy)-6,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methylheptoxy]-trimethylsilane. Molecular Formula: C36H68O3Si3. Molecular Weight: 633.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
2010-2012 NSDUH State-Specific Substate Region Estimates and Maps

This report provides State-specific tables and maps showing substate region prevalence estimates for 25 measures of substance use and mental disorders based on the 2010 to 2012 National Survey on Drug Use and Health (NSDUH). Results include past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older by 362 substate regions within the 50 States and the District of Columbia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).
Patent AT-E400984-T1: [Translated] DIGITAL CONTROL FOR FLUORESCENT LAMPS

A method to control the illumination intensity of a gas discharge lamp is achieved. The method comprises, first, converting an analog lamp illumination signal into a digital lamp illumination signal. The analog lamp illumination signal is a function of the illumination intensity of a gas discharge lamp. Second, digital target signal is subtracted from the digital lamp illumination signal to create a digital error signal. Third, a digital frequency set point is adjusted from a current value to a new value based on the digital error signal. The digital frequency set point is a high resolution digital value. Fourth, the current value and the new value are averaged by a digital delta sigma modulator to create a smoothed frequency set point. The smoothed frequency set point is a medium resolution value. Finally, an oscillating voltage signal is generated with a drive frequency based on the smoothed frequency set point. The drive frequency determines the illumination intensity of the gas discharge lamp.
Apoptosis and p53 expression in rat adjuvant arthritis

The kinetics of apoptosis and the apoptosis-regulating gene
			 p53 in adjuvant arthritis (AA) were investigated to assess the value
			 of the AA rat model for testing apoptosis-inducing therapies. Very few terminal
			 deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) nick
			 end-labeling (TUNEL)-positive cells were detected during the early phases of
			 AA, but on day 23 (chronic arthritis) the percentage of TUNEL-positive cells
			 was significantly increased. Expression of p53 in synovial tissue
			 gradually increased from days 5-23, which was markedly higher than p53
			 levels in rheumatoid arthritis (RA) synovium. Significant apoptosis only occurs
			 late in rat AA and is concordant with marked p53 overexpression,
			 making it useful model for testing proapoptotic therapies, but rat AA is not
			 the best model for p53 gene therapy because dramatic p53
			 overexpression occurs in the latter stages of the disease.
SDOH Measures for Census Tract, ACS 2017-2021

This dataset contains census tract-level social determinants of health (SDOH) measures from the American Community Survey 5-year data for the entire United States—50 states and the District of Columbia. Data were downloaded from data.census.gov using Census API and processed by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. These measures complement existing PLACES measures, including PLACES SDOH measures (e.g., health insurance, routine check-up). These data can be used together with PLACES data to identify which health and SDOH issues overlap in a community to help inform public health planning.  

To access spatial data, please use the ArcGIS Online service:  https://cdcarcgis.maps.arcgis.com/home/item.html?id=d51009ea78b54635be95c6ec9955ec17.
Compound 527385: 22,26-Dimethyl-triacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 23,27-dimethylhentriacontanenitrile. Molecular Formula: C33H65N. Molecular Weight: 475.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525874: N,N-Dimethyl-N'-(3-ethoxyphenyl)-isobutyramidine

Chemical compound data from PubChem database. IUPAC Name: N'-(3-ethoxyphenyl)-N,N,2-trimethylpropanimidamide. Molecular Formula: C14H22N2O. Molecular Weight: 234.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530358: Methyl 2-ethylcyclohexane-1-carboxylate

Chemical compound data from PubChem database. IUPAC Name: methyl 2-ethylcyclohexane-1-carboxylate. Molecular Formula: C10H18O2. Molecular Weight: 170.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Child Maltreatment 2022

This report presents national data about child abuse and neglect known to child protective services agencies in the United States during federal fiscal year 2022.

Letter from the Associate Commissioner

Acknowledgements

Summary

CHAPTER 1: Introduction

CHAPTER 2: Reports

CHAPTER 3: Children

CHAPTER 4: Fatalities

CHAPTER 5: Perpetrators

CHAPTER 6: Services

CHAPTER 7: Special Focus

APPENDIX A: CAPTA Data Items

APPENDIX B: Glossary

APPENDIX C: State Characteristics

APPENDIX D: State Commentary

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526235: 1,2,3,9-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,2,3,9-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Use of the direct puncture technique in management of capillaro-venous malformations: case report

Background
          Preoperative devascularization of the capillaro-venous malformations located in the aero-digestive tract is important for surgeons, to minimize blood loss during surgical excision of malformations.
        
        
          Case presentation
          Here we present two cases of capillaro-venous malformation in which we could successfully achieve preoperative devascularization, by directly injecting n-butyl cyano acrylate into the capillaro-venous bed. This technique is relatively easy, safe and cheap, and can be carried out immediately before surgery.
An MCASE approach to the search of a cure for Parkinson's Disease.

Background
          Parkinson's disease is caused by a dopamine deficiency state in the fore brain area. Dopamine receptor agonists, MAO-B inhibitors, and N-Methyl-D-Aspartate (NMDA) receptor antagonists are known to have antiparkinson effect. Levodopa, a dopamine structural analog, is the best currently available medication for the treatment of Parkinsons disease. Unfortunately, it also induces side effects upon long administration time. Thus, multidrug therapy is often used, in which various adjuvants alleviate side effects of levodopa and enhance its antiparkinsonian action.
        
        
          Results
          Computer models have been created for three known antiparkinson mechanisms using the MCASE methodology. New drugs for Parkinsons disease can be designed on the basis of these models. We also speculate that the presence of biophores belonging to different groups can be beneficial and designed some potential drugs along this line. The proposed compounds bear pharmacophores of MAO-B inhibitors, dopamine agonists and NMDA antagonists, which could synergistically enhance their antiparkinson effect.
        
        
          Conclusions
          The methodology could readily be expanded to other endpoints where drugs with multiple activity mechanisms would be desirable.
Debate: A subversive view of subsets - a dissident clinician's opinion

Clinical trialists and statisticians are very wary of subgroup analysis, for good reasons. Clinicians have to deal with situations in which subgroups of patients differ widely from one another in their prognosis and response to treatment. Few trials are large enough to demonstrate convincingly these differences in outcome, but often provide suggestive evidence. Should we ignore this and treat all patients as the same, or should we allow dubious statistical evidence to buttress biological plausibility in making clinical decisions?
Release of Crystalline Silica Nanoparticles During Engineered Stone Fabrication

Inhalation exposure to respirable crystalline silica (RCS) during fabrication of engineered stone-based kitchen countertops has been on the rise in recent years and has become a significant occupational health problem in the United States and globally. Little is known about the presence of nano-crystalline silica (NCS), i.e., particles below 100 nm. We present a methodology to quantify the crystalline silica content in the sub-100 nm size fraction of the aerosol released during engineered stone fabrication using X-ray diffraction (XRD) and Fourier transform Infrared (FT-IR) spectroscopy. Aerosol was generated in test chamber designed per EN 1093-3 and sampled using cascade impactors. XRD and FT-IR analysis showed the presence of both α-quartz (15 – 60 %) and cristobalite (10 – 50 %) polymorphs in all size fractions. With increasing particle size, the cristobalite content increased. 70 % of the total aerosol mass in the sub-100 nm fraction was found to be crystalline silica, qualitatively confirmed by electron diffraction and electron energy loss spectroscopy. Presence of other minerals was detected in all size fractions; no polymeric resin binder was detected in the sub-100 nm fraction. Although, the sub-100 nm fraction was about 1 % of the aerosol mass, it accounted for 4 – 24 % of the aerosol surface area based on total lung deposition. If the surface area is a more relevant exposure metric, the assessment of efficacy of current engineering control systems using mass as an exposure metric may not provide adequate protection.
Patent AT-E400240-T1: [Translated] SURGICAL APPARATUS FOR MINIMIZING ASTIGMATISM, MEASURED TOPOGRAPHICALLY AND REFRACTIVELY

A method of surgically treating an eye of a patient to correct astigmatism in which values of astigmatism are measured topographically and refractively, and limit values of targeted induced astigmatism for the topographically and refractively measured astigmatism values are obtained by summating the topographically value of astigmatism with the refractive value of astigmatism and vice versa. Respective target values of astigmatism for refraction and topography based on the limit values are obtained and surgical treatment is effected with a target induced astigmatism which is intermediate the limit values and provided respective topographical and refractive non-zero target astigmatism values whose sum is a minimum.
Compound 527163: 7,7-Dimethyl-6-methylene-tricyclo[6.2.1.01,5]undecan-2-one

Chemical compound data from PubChem database. IUPAC Name: 7,7-dimethyl-6-methylidenetricyclo[6.2.1.01,5]undecan-2-one. Molecular Formula: C14H20O. Molecular Weight: 204.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Indicators for 2023

2023: The CY 2023 Medicare Physician Fee Schedule has been updated by the annual PFS Final Rule for various new policies and for new and existing CPT/HCPCS codes for this latest calendar year. This includes implementing all recent legislation as directed by Congress and enacted by the Consolidated Appropriations Act (CAA) of 2023, signed into law of December 29, 2022, of which becomes effective starting January 1, 2023, with PFS conversion factor of $33.8872. The Geographic Practice Cost Index (GPCI) work floor of 1.0 continues to be extended through to the end of CY 2023.
Compound 530783: 4-Cyanobenzoic acid, 3,5-difluorophenyl ester

Chemical compound data from PubChem database. IUPAC Name: (3,5-difluorophenyl) 4-cyanobenzoate. Molecular Formula: C14H7F2NO2. Molecular Weight: 259.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Minneapolis: Drug-Related Emergency Department Visits, 2004-2011 - All Visits

Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits in the Minneapolis metropolitan area, covering 2004-2011. File includes all drug-related ED visits that are reportable to DAWN without regard for the reason for the visit or the specific drugs involved. It includes visits involving all forms of drug misuse or abuse plus visits resulting from adverse reaction, accidental ingestion, suicide attempts, and visits where patients were seeking detoxification services. These estimates are useful for looking at overall levels of drug involvement in ED visits.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol.  Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.
Centers for Medicare &amp; Medicaid Services (CMS) EHR Incentive Program Measures

The CMS EHR Incentive Programs provide incentives to eligible office-based providers and hospitals to adopt electronic health records. Both the Medicare and Medicaid programs have separate criteria and eligible participants. These measures track the percentage of physicians, nurse practitioners, physician assistants, short-term general, Critical Access, and Children's hospitals that have demonstrated meaningul use of certified electronic health record technology and/or adopted, implemented, or ugraded any electronic health record. These measures track the rate of adoption and use of EHR technology certified by HHS in addition to adoption of other non-certified EHR technology. These measures are cumulative, representing the most recent data.